Is indoleamine 2,3-dioxygenase important for graft acceptance in highly sensitized patients after combined auxiliary liver-kidney transplantation?

Transplantation

Volumn 88, Issue 7, 2009, Pages 911-919

  Ingelsten, Madeleine ^a   Gustafsson, Karin ^a   Oltean, Mihai ^b   Karlsson Parra, Alex ^a   Olausson, Michael ^b   Haraldsson, Börje ^a   Nyström, Jenny ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Combined liver kidney transplantation; Dendritic cells; Indoleamine 2,3 dioxygenase

Indexed keywords

EDETATE CHROMIUM CR 51; GAMMA INTERFERON; INDOLEAMINE 2,3 DIOXYGENASE; INTERLEUKIN 1BETA; KYNURENINE; MESSENGER RNA; TRYPTOPHAN; TUMOR NECROSIS FACTOR ALPHA;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DENDRITIC CELL; ENZYME ACTIVITY; FEMALE; GENE EXPRESSION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HISTOCOMPATIBILITY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HUMAN TISSUE; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIVER CELL; LIVER TRANSPLANTATION; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REPERFUSION;

ADULT; CELLS, CULTURED; DENDRITIC CELLS; FEMALE; GRAFT REJECTION; HEPATOCYTES; HUMANS; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; INTERFERON-GAMMA; INTERLEUKIN-1BETA; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 73249151775     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181b72e49     Document Type: Article

References (41)

1. Gordon RD, Fung JJ, Markus B, et al. The antibody crossmatch in liver transplantation. Surgery 1986; 100: 705.
2. Glotz D, Antoine C, Julia P, et al. Intravenous immunoglobulins and transplantation for patients with anti-HLA antibodies. Transpl Int 2004; 17: 1. (Pubitemid 38197020)
3. Higgins RM, Bevan DJ, Carey BS, et al. Prevention of hyperacute rejection by removal of antibodies to HLA immediately before renal transplantation. Lancet 1996; 348: 1208.
4. Jordan SC, Tyan D, Stablein D, et al. Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: Report of the NIH IG02 trial. J Am Soc Nephrol 2004; 15: 3256.
5. Montgomery RA, Zachary AA. Transplanting patients with a positive donor-specific crossmatch: A single center's perspective. Pediatr Transplant 2004; 8: 535.
6. Vieira CA, Agarwal A, Book BK, et al. Rituximab for reduction of anti-HLA antibodies in patients awaiting renal transplantation: 1. Safety, pharmacodynamics, and pharmacokinetics. Transplantation 2004; 77: 542. (Pubitemid 38282809)
7. Vo AA, Lukovsky M, Toyoda M, et al. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med 2008; 359: 242. (Pubitemid 352008439)
8. KamadaN.Theimmunologyofexperimentallivertransplantationintherat. Immunology1985;55:369.(Pubitemid15058228)
9. Gonwa TA, Nery JR, Husbcrg BS, et al. Simultaneous liver and renal transplantation in man. Transplantation 1988; 46: 690.
10. Olausson M, Mjornstedt L, Norden G, et al. Successful combined partial auxiliary liver and kidney transplantation in highly sensitized crossmatch positive recipients. Am J Transplant 2007; 7: 130. (Pubitemid 44952865)
11. Calne RY, Sells RA, Pena JR, et al. Induction of immunological tolerance by porcine liver allografts. Nature 1969; 223: 472.
12. Houssin D, Gigou M, Franco D, et al. Specific transplantation tolerance induced by spontaneously tolerated liver allograft in inbred strains of rats. Transplantation 1980; 29: 418. (Pubitemid 10037385)
13. Racanelli V, Rehermann B. The liver as an immunological organ. Hepatology 2006; 43(2 Suppl 1): S54.
14. Geissler EK, Korzun WJ, Graeb C. Secreted donor-MHC dass I antigen prolongs liver allograft survival and inhibits recipient anti-donor cytotoxic T lymphocyte responses. Transplantation 1997; 64: 782. (Pubitemid 27407113)
15. MunnDH,ZhouM,AttwoodJT,etal. Preventionofallogeneicfetalrejectionbytryptophancatabolism.Science1998;281:1191. (Pubitemid28406294)
16. AlexanderAM,CrawfordM,BerteraS,etal.Indoleamine2,3- dioxygenaseexpressionintransplanted NODIsletsprolongsgraftsurvivalafteradoptivetransferofdiabetogenicsplenocytes. Diabetes2002;51:356.(Pubitemid34764790)
17. Beutelspacher SC, Pillai R, Watson MP, et al. Function of indoleamine 2,3-dioxygenase in corneal allograft rejection and prolongation of allograft survival by over-expression. Eur J Immunol 2006; 36: 690.
18. Miki T, Sun H, Lee Y, et al. Blodtade of tryptophan catabolism prevents spontaneous tolerogenidty of liver allografts. Transplant Proc 2001; 33: 129. (Pubitemid 32237296)
19. Lechler R, Ng WF, Steinman RM. Dendritic cells in transplantation -Friend or foe? Immunity 2001; 14: 357. (Pubitemid 32441588)
20. Ueta H, Shi C, Miyanari N, et al. Systemic transmigration of allosensitizing donor dendritic cells to host secondary lymphoid organs after rat liver transplantation. Hepatology 2008; 47: 1352. (Pubitemid 351547921)
21. HwuP,DuMX,LapointeR,etal.Indoleamine2,3- dioxygenaseproductionbyhumandendriticcells resultsintheinhibitionofTcellproliferation.JImmunol2000;164:3596. (Pubitemid30169812)
22. Schrocksnadel K, Wirleitner B, Winkler C, et al. Monitoring tryptophan metabolism in chronic immune activation. Clin Chim Acta 2006; 364: 82. (Pubitemid 43120630)
23. Munn DH, Shafizadeh E, Attwood JT, et al. Inhibition of T cell proliferation by macrophage tryptophan catabolism. J Exp Med 1999; 189: 1363. (Pubitemid 29227522)
24. Matin A, Streete IM, Jamie IM, et al. A fluorescence-based assay for indoleamine 2,3-dioxygenase. Anal Biochem 2006; 349: 96.
25. Bjornson Granqvist A, Ebefors K, Saleem MA, ct al. Podocyte proteoglycan synthesis is involved in the development of nephrotic syndrome. Am J Physiol Renal Physiol 2006; 291: F722. (Pubitemid 44506968)
26. Ball HJ, Sanchez-Perez A, Weiser S, et al. Characterization of an indoleamine 2,3-dioxygenase-like protein found in humans and mice. Gene 2007; 396: 203. (Pubitemid 46818792)
27. Metz R Duhadaway JB, Kamasani U, et al. Novel tryptophan catabolic enzyme ID02 is the preferred biochemical target of the antitumor indoleamine 2,3-dioxygenase inhibitory compound D-1-methyl-tryptophan. Cancer Res 2007; 67: 7082. (Pubitemid 47206533)
28. Brandacher G, Cakar F, Winkler C, et al. Non-invasive monitoring of kidney allograft rejection through IDO metabolism evaluation. Kidney Int 2007; 71: 60. (Pubitemid 44967735)
29. Refaeli Y, Van Parijs L, Alexander SI, et al. Interferon gamma is required for activation-induced death of T lymphocytes. J Exp Med 2002; 196: 999.
30. Badovinac VP, Tvinnereim AR, Harty JT. Regulation of antigen-specific CD8+ T cell homeostasis by perforin and interferon-gamma. Science 2000; 290: 1354.
31. NovelliF,D'EliosMM,BernabeiP,etal.Expressionandroleinapoptosisofthealpha- andbeta-chainsoftheIFN-gammareceptoronhumanThIandTh2clones.JImmunol1997;159:206. (Pubitemid127493702)
32. VermeireK,HeremansH,VandeputteM,etal. AcceleratedcollageninducedarthritisinIFN-gammareceptor-deficientmice. JImmunol1997;158:5507.(Pubitemid127681260)
33. Manoury-SchwartzB,Chiocchia.G,BessisN,etal.Highsusceptibility-collagen- inducedarthritisinmicelackingIFN-gammareceptors.JImmunol1997;158:5501. (Pubitemid127681259)
34. Mele TS, Kneteman NM, Zhu LF, et al. IFN-gamma is an absolute requirement for spontaneous acceptance of liver allografts. Am J Transplant 2003; 3: 942.
35. Carlin JM, Borden EC, Sondel PM, et al. Biologic-response-modifierinduced indoleamine 2,3-dioxygenase activity in human peripheral blood mononuclear cell cultures. J Immunol 1987; 139: 2414.
36. Werner-FelmayerG,WernerER,FuchsD,etal. Tumournecrosisfactoralphaandlipopolysaccharideenhanceinterferon- inducedtryptophandegradationandpteridinesynthesisinhumancells. BiolChemHoppeSeyler1989;370:1063.(Pubitemid19230341)
37. Carlin JM, Weller JB. Potentiation of interferon-mediated inhibition of Chlamydia infection by interleukin-1 in human macrophage cultures. Infect Immun 1995; 63: 1870.
38. Edwards-Smith C, Goto S, Lord R, et al. Allograft acceptance and rejection, mediated by a. liver suppressor factor, LSF-1, purified from serum of liver transplanted rats. Transpl Immunol 1996; 4: 287. (Pubitemid 27019622)
39. Goto S, Lord R, Kobayashi E, et al. Novel immunosuppressive proteins purified from the serum of liver-retransplanted rats. Transplantation 1996; 61: 1147.
40. Nakano T, Kawamoto S, Lai CY, et al. Liver transplantation-induced antihistone H1 autoantibodies suppress mixed lymphocyte reaction. Transplantation 2004; 77: 1595. (Pubitemid 38703044)
41. Munn DH, Sharma MD, Baban B, et al. GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase. Immunity 2005; 22: 633. (Pubitemid 40719198)